82 related articles for article (PubMed ID: 38742103)
1. Proteomic, single-cell and bulk transcriptomic analysis of plasma and tumor tissues unveil core proteins in response to anti-PD-L1 immunotherapy in triple negative breast cancer.
Li Y; Yue L; Zhang S; Wang X; Zhu YN; Liu J; Ren H; Jiang W; Wang J; Zhang Z; Liu T
Comput Biol Med; 2024 Jun; 176():108537. PubMed ID: 38744008
[TBL] [Abstract][Full Text] [Related]
2. Evaluating immunotherapeutic outcomes in triple-negative breast cancer with a cholesterol radiotracer in mice.
Ciavattone NG; Guan N; Farfel A; Stauff J; Desmond T; Viglianti BL; Scott PJ; Brooks AF; Luker GD
JCI Insight; 2024 Mar; 9(8):. PubMed ID: 38502228
[TBL] [Abstract][Full Text] [Related]
3. A comprehensive single-cell breast tumor atlas defines epithelial and immune heterogeneity and interactions predicting anti-PD-1 therapy response.
Xu L; Saunders K; Huang SP; Knutsdottir H; Martinez-Algarin K; Terrazas I; Chen K; McArthur HM; Maués J; Hodgdon C; Reddy SM; Roussos Torres ET; Xu L; Chan IS
Cell Rep Med; 2024 May; 5(5):101511. PubMed ID: 38614094
[TBL] [Abstract][Full Text] [Related]
4. Combination of proton- or X-irradiation with anti-PDL1 immunotherapy in two murine oral cancers.
Rykkelid AM; Sinha PM; Folefac CA; Horsman MR; Sørensen BS; Søland TM; Schreurs OJF; Malinen E; Edin NFJ
Sci Rep; 2024 May; 14(1):11569. PubMed ID: 38773258
[TBL] [Abstract][Full Text] [Related]
5. The Great Immune Escape: Understanding the Divergent Immune Response in Breast Cancer Subtypes.
Onkar SS; Carleton NM; Lucas PC; Bruno TC; Lee AV; Vignali DAA; Oesterreich S
Cancer Discov; 2023 Jan; 13(1):23-40. PubMed ID: 36620880
[TBL] [Abstract][Full Text] [Related]
6. Sonogenetics-controlled synthetic designer cells for cancer therapy in tumor mouse models.
Gao T; Niu L; Wu X; Dai D; Zhou Y; Liu M; Wu K; Yu Y; Guan N; Ye H
Cell Rep Med; 2024 May; 5(5):101513. PubMed ID: 38608697
[TBL] [Abstract][Full Text] [Related]
7. Mathematical modeling and analysis of cancer treatment with radiation and anti-PD-L1.
Liao KL; Wieler AJ; Gascon PML
Math Biosci; 2024 May; ():109218. PubMed ID: 38797473
[TBL] [Abstract][Full Text] [Related]
8. ASO Author Reflections: Immune-Related Adverse Events During Neoadjuvant Chemoimmunotherapy for Triple-Negative Breast Cancer May Influence Time to Adjuvant Radiation.
Myers SP; Downs-Canner SM
Ann Surg Oncol; 2024 May; ():. PubMed ID: 38776008
[No Abstract] [Full Text] [Related]
9. Neoadjuvant radiotherapy in ER
Bruss C; Albert V; Seitz S; Blaimer S; Kellner K; Pohl F; Ortmann O; Brockhoff G; Wege AK
Front Immunol; 2024; 15():1355130. PubMed ID: 38742103
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapy-free radiotherapy combined with immune checkpoint inhibitors: a new regimen for locally advanced non-small cell lung cancer?
Ma L; Deng L; Peng J; Yu J; Meng X
Cancer Biol Med; 2024 Feb; 20(12):1035-46. PubMed ID: 38318930
[TBL] [Abstract][Full Text] [Related]
11. Predictive factors for response to neoadjuvant chemotherapy: inflammatory and immune markers in triple-negative breast cancer.
Kusama H; Kittaka N; Soma A; Taniguchi A; Kanaoka H; Nakajima S; Oyama Y; Seto Y; Okuno J; Watanabe N; Matsui S; Nishio M; Fujisawa F; Honma K; Tamaki Y; Nakayama T
Breast Cancer; 2023 Nov; 30(6):1085-1093. PubMed ID: 37782377
[TBL] [Abstract][Full Text] [Related]
12. The multifunctional protein HMGB1: 50 years of discovery.
Tang D; Kang R; Zeh HJ; Lotze MT
Nat Rev Immunol; 2023 Dec; 23(12):824-841. PubMed ID: 37322174
[TBL] [Abstract][Full Text] [Related]
13. Immune Checkpoint Profiling in Humanized Breast Cancer Mice Revealed Cell-Specific LAG-3/PD-1/TIM-3 Co-Expression and Elevated PD-1/TIM-3 Secretion.
Bruss C; Kellner K; Albert V; Hutchinson JA; Seitz S; Ortmann O; Brockhoff G; Wege AK
Cancers (Basel); 2023 May; 15(9):. PubMed ID: 37174080
[TBL] [Abstract][Full Text] [Related]
14. An increase in tumor-infiltrating lymphocytes after treatment is significantly associated with a poor response to neoadjuvant endocrine therapy for estrogen receptor-positive/HER2-negative breast cancers.
Fukui R; Watanabe T; Morimoto K; Fujimoto Y; Nagahashi M; Ishikawa E; Hirota S; Miyoshi Y
Breast Cancer; 2023 Sep; 30(5):703-713. PubMed ID: 37115435
[TBL] [Abstract][Full Text] [Related]
15. High tumor mutational burden predicts favorable response to anti-PD-(L)1 therapy in patients with solid tumor: a real-world pan-tumor analysis.
Jung J; Heo YJ; Park S
J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37094985
[TBL] [Abstract][Full Text] [Related]
16. The chemokines CXCL8 and CXCL12: molecular and functional properties, role in disease and efforts towards pharmacological intervention.
Cambier S; Gouwy M; Proost P
Cell Mol Immunol; 2023 Mar; 20(3):217-251. PubMed ID: 36725964
[TBL] [Abstract][Full Text] [Related]
17. Radiation-induced PD-L1 expression in tumor and its microenvironment facilitates cancer-immune escape: a narrative review.
Wang NH; Lei Z; Yang HN; Tang Z; Yang MQ; Wang Y; Sui JD; Wu YZ
Ann Transl Med; 2022 Dec; 10(24):1406. PubMed ID: 36660640
[TBL] [Abstract][Full Text] [Related]
18. Impact of adjuvant chemotherapy and radiotherapy on tumour-infiltrating lymphocytes and PD-L1 expression in metastatic breast cancer.
Yazaki S; Salgado R; Shimoi T; Yoshida M; Shiino S; Kaneda T; Kojima Y; Sumiyoshi-Okuma H; Nishikawa T; Sudo K; Noguchi E; Murata T; Takayama S; Suto A; Ohe Y; Yonemori K
Br J Cancer; 2023 Feb; 128(4):568-575. PubMed ID: 36522476
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
